← Russell 3000 cross-section

MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$1.3bn
Revenue TTM
$209m
Net income TTM
$-77m
Free cash flow
$-35m
Composite score
29.4
Sector rank
#1862

Valuation

P / E
EV / EBITDA
EV / sales
6.8
FCF yield
-2.62%
Earnings yield vs 10-yr
-10.50pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-37.1%
EBITDA margin
-32.7%
ROE
-37.8%
ROIC
-41.7%
Revenue growth
-3.3%

Insider activity, last 90 days

Net open-market
$-0.25m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

During the three and six months ended June 30, 2026, the Company recognized revenue of $ 0.8 million and $ 1.5 million, respectively, that was included in the contract liabilities balances as of December 31, 2025. During the three and six months ended June 30, 2025, the Company recognized revenue of $ 0.6 million and $ 1.5 million, respectively, that was included in the contract liabilities balances as of December 31, 2024. …MARAVAI LIFESCIENCES HOLDINGS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →